Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pisa – page 7

582 clinical trials in Pisa, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pisa at a glance
582
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

582 trials in Pisa

Open in trial search

Angelman's syndrome

Recruiting

A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
  • Sponsor:Ionis Pharmaceuticals Inc.

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Prophylaxis of nausea and vomiting+1

Recruiting

A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Aprepitant
  • Sponsor:Eli Lilly & Co.

Clostridium difficile infection

Recruiting

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5148
  • Sponsor:AstraZeneca AB

K-ras gene mutation+1

Recruiting

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Genentech Inc.

Gastrooesophageal cancer

Recruiting

Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Interstitial lung disease

Recruiting

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Endocrine ophthalmopathy

Recruiting

Study of K1-70 compared to placebo for patients with active thyroid eye disease from Graves' disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 monoclonal antibody against thyrotropin receptor
  • Sponsor:Av7 Limited

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Bacterial vaginosis

Recruiting

A study comparing furazidin and clindamycin for women with bacterial vaginosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Clindamycin Phosphate
  • Sponsor:Adamed Pharma S.A.

Myotonic dystrophy

Recruiting

A study testing the safety and effects of ADS-019 in adults aged 18 to 65 years with type 1 myotonic dystrophy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:ADS-019
  • Sponsor:Sarepta Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Pisa

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Investigating innovative treatments for cardiac conditions and metabolic disorders, with studies focusing on TTR amyloidosis cardiomyopathy and chronic kidney disease management.

  • Heart Disease Therapeutics
  • Kidney Disease Management
  • Hypertension Control

Current trials evaluate novel compounds for improving patient outcomes in cardiac conditions and renal disorders.

02 Oncology Studies

Comprehensive research into various cancer types, including colorectal cancer, gastric cancer, and lung cancer, testing targeted therapies and innovative treatment combinations.

  • Metastatic Cancer Treatment
  • Targeted Therapy Development
  • Immunotherapy Research

Advanced clinical trials exploring breakthrough treatments for multiple cancer types.

03 Autoimmune & Inflammatory Conditions

Studies focusing on chronic inflammatory conditions including Sjögren's Syndrome, psoriatic arthritis, and hidradenitis suppurativa.

  • Inflammatory Disease Management
  • Autoimmune Treatment Innovation
  • Novel Therapeutic Approaches

Evaluating new therapeutic options for improving quality of life in patients with chronic inflammatory conditions.

04 Respiratory & Infectious Diseases

Research into respiratory conditions and infectious diseases, including studies on chronic rhinosinusitis and respiratory syncytial virus infections.

  • Respiratory Disease Treatment
  • Infection Management
  • Vaccine Development

Investigating new approaches to treat and prevent respiratory infections and related conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.